surfaxinBiotech alum William Roberts has moved to publicly traded Discovery Laboratories as VP of IR and corporate communications for the Warrington, Pa.-based company focused on respiratory disease care.

Discovery in November launched premature infant respiratory distress syndrome treatment Surfaxin in the U.S. Its Aerosurf treatment for RDS is in phase 2 clinical trials.

Roberts was VP-corporate comms. with oversight of IR at ViroPharma, which was acquired in January in a $4.2B deal by Shire. He was associate director of IR among other posts during 12 years at MedImmune.

Net loss for the fourth quarter 2013 was $11.7M.

Roberts reports to president/CEO John Cooper. In a statement, Cooper said Roberts will "coalesce our communications strategies so our customers and stakeholders fully understand the value and vision of Surfaxin and Aerosurtf.

Pharmaceutical PR vet Michael Parks advised the launch of Surfaxin through his Philadelphia-based Pitch360 firm. New York-based LifeSci Advisors was outside IR counsel.